Page last checked 2026-08-17

Being studied in people · not FDA-approved

Mazdutide

Mazdutide is a once-weekly injection that works on two hormone receptors at once, GLP-1 and glucagon. It is the same class idea as tirzepatide, with a different second target.

What matters first

Why people look it up: In China it is prescribed for weight and for type 2 diabetes. Everywhere else it is sold online to people who want the newest weight-loss injection.
What the evidence shows: The trial program is large, and every trial in it was run in China. Two phase 3 trials compared it against placebo and reported substantial weight reduction. An independent review of nine trials says longer-term, multi-ethnic data is still needed. Nobody outside a Chinese pharmacy is getting the approved product.
Dose status: Mazdutide was given at 4–6 mg once a week, stepped up from 2 mg in four-week stages in the trials below. China approved it in June 2025 as Xinermei. The United States has not, and FDA holds no label for it. Nobody here has read the approved label either, so every number on this page is a trial arm rather than a schedule.

Evidence snapshot

Published human trial

The fastest way to see what kind of evidence this page is built on.

Regulation: Approved in ChinaNot FDA-approved · Xinermei
Dose source: Human trial arms2 arms · not a schedule
Safety evidence: 6 listed safety findingsCommon and serious effects shown apart
Sources: 8 cited sourcesMedical review complete · 2026-08-17

Open the shareable evidence image

Mazdutide at a glance: published human trial, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Further down: research and dosing details · how it works · how good the evidence is · questions

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-17open the primary sources

What is known about Mazdutide

Mazdutide is a once-weekly injection acting on two receptors at once, GLP-1 and glucagon. China approved it in June 2025 for weight, and in September 2025 for type 2 diabetes, where it sells as Xinermei. The United States has not approved it, and FDA holds no label for it. Its phase 3 obesity trials gave 4 mg and 6 mg a week, and one gave 9 mg. Innovent Biologics developed it with Eli Lilly, and registries file it as IBI362 and LY3305677.

Mazdutide research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
Topic	Value
Strongest source	Human trial
FDA approval	Not FDA-approved — approved in China since June 2025 as Xinermei
Studied dosing	4–6 mg once weekly, stepped up from 2 mg in four-week stages — from clinical trials
Studied dosing	9 mg once weekly for 60 weeks, the single arm of a second phase 3 trial, reached by a gradual climb the report does not detail — from clinical trials
Studied dosing	4–6 mg once weekly for 24 weeks against placebo, then 24 weeks of open treatment; a separate trial ran the same doses against dulaglutide — from clinical trials
Studied dosing	3–6 mg once weekly for 24 weeks across three arms, in the dose-finding trial that chose the doses every later trial used — from clinical trials
Studied dosing	9–10 mg once weekly in four-week stages: 3 then 6 then 9 mg over twelve weeks, or 2.5 then 5 then 7.5 then 10 mg over sixteen — from clinical trials
Typical vials	10 mg

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

How Mazdutide works

Mazdutide acts at glucagon + GLP-1. Here is what that means.

This pairing drops GIP and keeps glucagon: one signal that cuts what you take in, one that raises what you burn. It is the most direct of the combinations, because the two hormones pull on opposite ends of the energy balance instead of pushing on the same end. It is also the pairing with the most obvious internal conflict, since glucagon works against the blood-sugar lowering it is packaged with.

◆ Receptor targets2 of 4 · glucagon + GLP-1

4What each receptor does — 4 rows in the data table

Receptors targeted by Mazdutide, and what each receptor does
Receptor	Mazdutide	What it does
GLP-1	targeted	Less appetite, slower stomach emptying, and insulin while blood sugar is rising. Here the insulin arm does double duty — it also counters glucagon’s tendency to push blood sugar up.
GIP	not targeted	—
Glucagon	targeted	hepatocytesRaises how much energy you burn and makes the liver burn fat. That liver effect is why drugs in this class are also being tested in fatty-liver disease, not just for weight.
Amylin	not targeted	—

The same four receptor groups are shown for every drug, so the differences are easy to compare. Targets come from the drug class. Any result specific to Mazdutide comes from the cited sources.

One arm raises blood sugar while the other pushes it down. The balance between them is the core of the design. It also means these drugs cannot be compared with incretin-only drugs milligram for milligram. Trials raise the dose slowly because both mechanisms need to be introduced over time. A shorter ramp-up is not what those trials tested.

What the evidence for Mazdutide is

These numbers come from a study in people that was published in a peer-reviewed journal. The drug or dose may still be experimental and may not have FDA approval.

Human trial

The trial behind the numbers

48-week phase 3 obesity trial · 610 participants · 48 weeks

Ji L et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med 2025;392:2215-2225 (GLORY-1, NCT05607680, PMID 40421736) · retrieved 2026-08-17

What it establishes: The study gave known doses to a defined group, monitored what happened and compared the results with another group.
What it does not establish: One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

Read each result with the study length, dose and number of participants. Results from separate trials are not a direct comparison because the people and study designs differ.

What each dose produced in the trial

These are the doses the trial gave and the weight change it reported for each one. It is a record of one experiment, not a schedule — no regulator has reviewed any of these doses.

◆ 48-week phase 3 obesity trial610 participants · 48 weeks

Average weight change from the start of the trial, by weekly dose · the dashed rule marks placebo

4 mg−11.0%

2 mg weekly for 4 weeks, then 4 mg weekly for 44 weeks. One step, held four weeks, then the rest of the year at the target. This is the lower of the two arms, the shorter climb, and the one that reached its dose soonest

6 mg−14.0%

2 mg for 4 weeks, then 4 mg for 4 weeks, then 6 mg weekly for 40 weeks. Two months of lower doses before this arm’s own dose begins, which is a sixth of the trial spent under the amount the arm is named for

Placebo+0.3%

3Exact trial values — 3 rows in the data table

Mazdutide — 48-week phase 3 obesity trial: average weight change from the start for each dose group
Once-weekly dose	Study group	Average weight change	What the paper notes
4 mg	Active	−11.0%	2 mg weekly for 4 weeks, then 4 mg weekly for 44 weeks. One step, held four weeks, then the rest of the year at the target. This is the lower of the two arms, the shorter climb, and the one that reached its dose soonest
6 mg	Active	−14.0%	2 mg for 4 weeks, then 4 mg for 4 weeks, then 6 mg weekly for 40 weeks. Two months of lower doses before this arm’s own dose begins, which is a sixth of the trial spent under the amount the arm is named for
Placebo	Control	+0.3%	The group used to compare every active dose

What the source does not report for each dose group

These are the week-48 figures, and the trial measured its own main endpoint earlier, at week 32. There the arms read −10.09% and −12.55%, against +0.45% on placebo, so weight was still coming off between the two dates. Four in five of the higher arm lost at least 5% of their weight by week 32, and about half lost at least 15% by week 48. A second phase 3 trial gave 9 mg a week to 307 people for 60 weeks, reporting −16.65% against −1.50% on placebo. The steps in each arm are quoted from its own registry entry, because the trial paper is not open access.

Source: Ji L et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med 2025;392:2215-2225 (GLORY-1, NCT05607680, PMID 40421736) · retrieved 2026-08-17 · every value is quoted from that paper. Trial results describe averages across a study population, not an individual outcome.

Some bars are missing on purpose. Where the paper gives a range across arms instead of a figure per arm, that arm is left unplotted rather than filled in with a guess. The dashed line marks the placebo arm, so the part of each bar past it is the part the trial puts down to the drug rather than to being in a study.

How the trial reached those doses, step by step →

Where Mazdutide is in clinical trials

39 registered studies; the program has reached phase 4, and 10 are still enrolling.

The soonest a running study expects to finish measuring people is September 2026. That is when the sponsor expects to finish collecting the main measurement. It is not a results date, and not a date anything goes on sale.

Phase 4Not yet recruiting
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
Huijie Zhang · Type 2 Diabetic Kidney Disease · 820 participants planned · started September 2026
Main measurement due February 2029 (sponsor estimate)
NCT07775846 on ClinicalTrials.gov
Phase 4Not yet recruiting
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
Shandong Provincial Hospital · Prediabetes, Impaired Fasting Glucose · 150 participants planned · started July 2026
Main measurement due June 2028 (sponsor estimate)
NCT07654062 on ClinicalTrials.gov
Phase 4Not yet recruiting
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
China National Center for Cardiovascular Diseases · Obesity & Overweight, Coronary Heart Disease · 116 participants planned · started May 2026
Main measurement due October 2027 (sponsor estimate)
NCT07657676 on ClinicalTrials.gov

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-08-23

Every compound we track, and what stage each one has reached →

Regulatory status

This is the one compound on this site approved somewhere and not here.

China approved mazdutide in June 2025 for weight, and in September 2025 for type 2 diabetes. It is sold there as Xinermei. That approval governs a Chinese pharmacy and nothing else.

FDA has approved no mazdutide product, and a Drugs@FDA search on 13 August 2026 found nothing under any of its four names. The drug is dispensed under supervision several thousand miles away. Anything reaching a US reader outside that is unapproved and unchecked.

No schedule is copied from the Chinese label, because nobody here has read it.

Full regulatory tracker →

Where to go next on Mazdutide

The schedule, the side effects and the mixing math each have their own page.

Which mazdutide amounts the trials actually gave

48-week phase 3 obesity trial for mazdutide: 610 participants over 48 weeks.

When mazdutide reactions tend to appear

Published human trial data behind the mazdutide safety page.

Mazdutide concentration and dose-draw tool

The concentration in mg/mL for every mazdutide vial and water pairing, printed in full.

What each water volume does to the 10 mg mazdutide vial

Every option for the 10 mg mazdutide vial, with an example draw on a U-100 barrel.

Who else is sold for weight loss besides mazdutide

What people take it for and what the weight loss page shows stay in separate columns, including mazdutide

Check the same draw on a vial that is not mazdutide

Any vial at all, mazdutide among them, with the arithmetic shown rather than hidden.

The source-checked VK2735 entry, beyond the mazdutide one

No regulator has approved VK2735 — beyond mazdutide.

Zenagamtide on its own page, separate from mazdutide

Zenagamtide has published human trial data, separate from mazdutide.

What the tirzepatide page carries, separate from mazdutide

15 sourced tirzepatide reactions, on its own page, separate from mazdutide.

What the cagrilintide page carries, separate from mazdutide

4 sourced cagrilintide reactions, on its own page, separate from mazdutide.

Safety notes

Approved in China, not in the United States. FDA has approved no mazdutide product and holds no label for it. A Drugs@FDA search on 13 August 2026 found nothing under any of its four names
At 10 milligrams in 2 milliliters, the draw for 6 mg is 1.2 mL and for 9 mg is 1.8 mL. Neither fits a 1 mL barrel, so the common habit of mixing into 2 mL does not work at this compound’s upper doses
Nobody here has read the approved Chinese label. Every quantity on this page is a trial arm from a published paper. That is why no dosing schedule is printed as one
Every result was measured in Chinese adults. An independent 2026 review of nine trials says longer and more varied studies are still needed. It names durability, wider populations and heart safety as the open questions
Participants also started lighter than a US obesity trial would enroll. The average was 87.2 kg in one phase 3 trial and 94.0 kg in the other. A percentage of body weight is a percentage of the body it was measured in
Trial doses are study information, not a recommendation
Gut reactions were the rule rather than the exception at the highest dose. More than half the 9 mg group reported vomiting, and nearly half reported nausea
The climb in the trials was slow. Each step lasted four weeks, and reaching 6 mg took eight weeks of lower doses first. Faster increases were not studied
The same two doses run through the diabetes trials as through the obesity ones. So a milligram figure for this compound does not say which trial it came from, or which question it was answering
The 9 mg figure comes from one trial with a single dose group. It did not compare 9 mg with a lower dose, so the study cannot tell us what the step up from 6 mg changes
The dose-finding trial that chose these amounts ran 3 mg, 4.5 mg and 6 mg for 24 weeks in 248 people. The 4.5 mg arm went no further, so it has a published result and no later trial behind it
The comparison most readers want is against semaglutide. Two phase 3 trials running exactly that comparison are registered and one of them has finished, but no result from either has been published
Doses above 9 mg have been given only in small early trials. One gave 10 mg to eight people. Another climbed 24 people toward a 16 mg target over twenty weeks. A figure above that range has nothing behind it
Employees of Innovent Biologics are co-authors on every trial cited here. That is ordinary for a drug company’s own program. It is also why an independent review is cited beside them
This acts on the glucagon receptor as well as GLP-1. That is what separates it from semaglutide and tirzepatide. The second receptor is not simply extra weight loss, and what it does over years is not settled in anyone
Anything sold under this name outside a Chinese pharmacy is not the approved product. No regulator anywhere has looked at what is in the vial

Questions about Mazdutide

Is Mazdutide FDA-approved?

No — not in the United States, and FDA holds no label for it. China approved it in June 2025, sold there as Xinermei, so an approved dose does exist — just not one any US pharmacy dispenses, and not one anybody here has read the label for. The regulatory status section above has the detail.

How is Mazdutide taken?

By injection under the skin, once a week, stepped up from 2 mg in four-week stages. The dosing page has every step, with the source on each row.

How does Mazdutide differ from the other compounds in this class?

It acts at glucagon + GLP-1. The nearest alternatives act elsewhere: Tirzepatide (GIP + GLP-1), Semaglutide (GLP-1 alone), Liraglutide (GLP-1 alone), Retatrutide (GIP + GLP-1 + glucagon), Cagrilintide (amylin), VK2735 (GIP + GLP-1), Zenagamtide (GLP-1 + amylin). Adding or removing a receptor changes both the effect and how much of it people can tolerate, so these molecules are not swappable at the same number of milligrams. Comparing them milligram for milligram is the most common mistake in this category.

What is not known about Mazdutide?

One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

For this compound specifically: These are the week-48 figures, and the trial measured its own main endpoint earlier, at week 32. There the arms read −10.09% and −12.55%, against +0.45% on placebo, so weight was still coming off between the two dates. Four in five of the higher arm lost at least 5% of their weight by week 32, and about half lost at least 15% by week 48. A second phase 3 trial gave 9 mg a week to 307 people for 60 weeks, reporting −16.65% against −1.50% on placebo. The steps in each arm are quoted from its own registry entry, because the trial paper is not open access.

Is there a Mazdutide dosing schedule on this site?

Not a schedule — there is no FDA-approved schedule to publish here. What you get instead is the trial dosing program: the doses each arm received and how the protocol worked up to them. The studied range was 4–6 mg once a week, stepped up from 2 mg in four-week stages. See what the trials tested.

8primary sources, each with the day we read it — open the documents used on this page